Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies

The DIPSS Plus and Myeloproliferative Neoplasm Symptom Assessment Form are used to inform treatment regimen decisions[7, 15]. For patients with asymptomatic low-risk or intermediate-1 disease, observation is generally recommended[5, 16]. For symptomatic patients, current therapies include allogeneic hematopoietic stem cell transplant (HSCT) and palliative treatments that help alleviate disease symptoms such as anemia and splenomegaly[5, 16, 17]. Allogeneic HSCT is associated with significant risk of morbidity and mortality due to relapse, infection, and graft-versus-host disease, and therefore is recommended only for patients aged < 65 years with intermediate- or high-risk disease[18]. Reduced-intensity conditioning regimens have shown more favorable outcomes but still pose a high risk for patients aged > 55 years and patients with mismatched donors[19].

Therapies intended to treat MF-associated anemia include growth factors (eg, erythropoietin), androgens (eg, danazol), and the immunomodulatory drugs (IMiDs) thalidomide (± prednisone), lenalidomide (± prednisone), and pomalidomide (± prednisone)[20‐26]. IMiDs have also been shown to improve splenomegaly[27‐29]. Other agents used to treat MF-associated splenomegaly include the nonspecific oral myelosuppressive agent hydroxyurea, the oral alkylators melphalan and busulfan, and the purine nucleoside analog 2-CdA[30‐32]. Hydroxyurea is a choice for splenomegaly in patients with MF as well[5]. Although generally well tolerated, hydroxyurea can lead to myelosuppression, which can exacerbate MF-associated anemia[14, 16].

Based on the finding that the majority of patients with MF have a mutation in JAK2, numerous inhibitors of JAK2 (ruxolitinib [INCB018424], fedratinib [SAR302503; TG101348], lestaurtinib [CEP-701], momelotinib [CYT387], pacritinib [SB1518], AZD1480, BMS-911543, gandotinib [LY2784544], AT9283, and XL019) have been developed and are being evaluated in clinical trials. Of note, JAK inhibitors also have activity in JAK2 nonmutated MF/PMF[33, 34]. Ruxolitinib, an inhibitor of JAK1 and JAK2, was approved in 2011 by the US Food and Drug Administration (FDA) for use in patients with intermediate- or high-risk MF (PMF, post-PV MF, and post-ET MF) and in 2012 by Health Canada and the European Medicines Agency for the treatment of MF-related splenomegaly and symptoms[35‐37]. JAK2 inhibitors differ according to their specificity for JAK2 and have variable efficacy and toxicity profiles[5, 17].

Currently, the only potentially curative therapy for patients with MF is allogeneic HSCT[16, 38]. Due to treatment-related morbidity and mortality, HSCT is recommended for patients with intermediate-2– or high-risk disease who are fit enough to undergo the procedure. The majority of patients with MF are treated with palliative therapies, which improve disease symptoms rather than altering the natural history of disease[17]. The discovery of the JAK2 gain-of-function mutation, JAK2 V617F[39‐42], followed by the development and approval of ruxolitinib has marked a new era in the treatment of MF, providing improved symptomatic responses and quality of life in comparison with traditional therapies[36, 37, 43‐45]. However, treatment with JAK2 inhibitors has shown only limited evidence of disease modification–JAK2 inhibitors do not improve bone marrow fibrosis and most provide limited reduction of JAK2 V617F allelic burden[16, 17]. Ruxolitinib appears to block inflammatory cytokine activity rather than stem cell–derived clonal myeloproliferation, which is the primary driver of the disease[46]. Therefore, disease resistance can ensue following an initial response to JAK2 inhibition[16, 46]. In addition, treatment-related anemia may exacerbate preexisting MF-related anemia[33, 43, 44].

To further improve the responses to JAK2 inhibitors, various combinations have been clinically tested. For example, combination of JAK2 inhibitors with agents that improve anemia (eg, IMiDs) or target signaling pathways involved in proliferation, survival, and self-renewal may further improve the outcome of patients with MF[26, 47‐49]. Combinations of JAK2 inhibitors with inhibitors of the hedgehog (Hh) pathway, which plays a role in the maintenance of cancer stem cells[50], could provide an avenue of targeting stem cell–derived clonal myeloproliferation (which evades JAK2-targeted monotherapy)[51]. Other combination partners, including hypomethylating agents (Tibes, unpublished observation) and Aurora-kinase inhibtors have also been proposed[52]. The preclinical rationale and current clinical evidence supporting use of Hh pathway–targeted therapies in the treatment of patients with MF will be discussed herein.

The Hh signaling pathway plays a role in proliferation, differentiation, and survival during embryonic development and in tissue and stem cell maintenance in the adult[50, 53]. Hh signaling is initiated when one of 3 ligands–sonic hedgehog (SHH), Indian hedgehog (IHH), or desert hedgehog (DHH)–binds to patched (PTCH), a 12-transmembrane receptor, relieving its inhibition of smoothened (SMO), a 7-transmembrane G-like protein–coupled receptor (Figure 1A). SMO then translocates to the primary cilium and activates the glioma-associated oncogene homolog (GLI) transcription factors, a process that involves their release from a repressor complex including suppressor of fused. Once released, GLIs translocate to the nucleus to regulate the transcription of target genes including GLI1/2, PTCH, cyclin D1, and B-cell CLL/lymphoma 2.

Hh signaling is required during hematopoiesis (Figure 2); however, its exact role is not completely understood and may differ depending on the stage of hematopoiesis, cell type (stem, primitive, or differentiated cell), and physiological state[54]. During primitive hematopoiesis, when embryonic mesoderm is committed to becoming hematopoietic precursors (eg, erythrocytes) and blood islands begin to form[55, 56], Ihh is expressed in the visceral endoderm surrounding the epiblast and in the endodermal layer of the mature yolk sac and induces the expression of Ptch1, Smo, and Gli1 within these tissues[57]. Murine Ihh knockout mice and in vitro studies in Ihh- deficient embryonic stem cell lines suggest that Ihh is required for hematopoiesis and vasculogenesis[57‐60]. Survival of half of Ihh^−/− mice and the observation that Smo^−/− mice die earlier suggest that Dhh and/or Shh may also play a role in primitive hematopoiesis and vasculogenesis[57, 61].

Preclinical studies also suggest that Hh plays a role not only in establishing definitive hematopoiesis, which is characterized by formation of multipotent hematopoietic stem cells (HSCs), but also in the proliferation and differentiation of HSCs (Table 1)[62‐70]. Activated Hh signaling through loss of Ptch leads to increased HSC formation and activity[64, 66], enhanced recoverability following treatment with 5-fluorouracil[65, 66], and increased regeneration capacity[65, 66]. Conversely, loss of pathway activity through mutation of the downstream effector, Gli1, in mice leads to decreased proliferation of long-term HSCs and myeloid progenitors, reduced myeloid differentiation, and delayed recovery following 5-fluorouracil treatment[69]. Interestingly, reduced HSC activity (through loss of Gli1) led to increased engraftment. Together, these studies suggest that inhibition of the Hh pathway at different nodes (ie, Smo vs Gli1) affects hematopoiesis differently.

The role of Hh signaling in long-term HSCs is not well understood—several groups have reported conflicting results (Table 1); however, in each study, activated Hh signaling led to aberrant hematopoiesis[65‐67]. There have also been some discrepancies in studies involving deletion of Smo, based on the temporal expression pattern of the experimental driver used (embryogenesis vs adulthood) and its specificity (hematopoietic and endothelial tissue vs HSCs, lymphocytes, and liver cells)[65, 68, 73, 74]. Disruption of Hh signaling earlier and in more tissues affected HSC function, whereas disruption of Hh signaling in adult HSCs had no effect, suggesting that Hh signaling may be important during early definitive hematopoiesis.

Numerous studies have also presented evidence implicating the Hh pathway in the maintenance or homeostasis of hematopoietic precursors[72, 75‐79]. Activated Hh signaling in nonhematopoietic cells (ie, epithelial cells or marrow niche cells) led to apoptosis of lymphoid progenitors or an increase in the number of lineage-negative bone marrow cells and increased mobilization of myeloid progenitors[67]. Inhibition of Hh signaling in marrow stromal cells led to impaired differentiation of B-lymphoid cells from hematopoietic progenitors—the number of myeloid progenitors was increased at the expense of lymphoid progenitors[72]. These and several other studies suggest that Hh signaling may be required in a noncell autonomous manner where Hh signaling functions in the nonhematopoietic bone marrow cells (ie, stroma or epithelial cells) surrounding HSCs to maintain, particularly myeloid, hematopoietic precursors (Figure 2)[67, 72, 76‐79].

To date, preclinical data on the potential role of the Hh pathway in MF are limited. However, in one study, expression of GLI1 and PTCH1 were shown to be increased up to 100-fold in granulocytes isolated from patients with MPNs compared with control granulocytes[51]. The Hh pathway was also shown to be up-regulated in a mouse bone marrow transplant model[51]. In this same model, mice were treated with vehicle, ruxolitinib, or a combination of ruxolitinib and the SMO inhibitor sonidegib (LDE225), for 28 days[51]. Combination therapy resulted in increased efficacy in MPNs—causing a greater reduction of mutant allele burden in the bone marrow, reduced bone marrow fibrosis, lower white blood cell count, and lower platelet count than treatment with vehicle or ruxolitinib alone (Table 2). Moreover, in the Gata1 ^low mouse model of MF, gene expression analysis of the spleen and bone marrow identified alterations in the expression of bone morphogenetic protein 4, an indirect target of the Hh pathway, further supporting a role for Hh signaling in MF[80, 81].

There are many preclinical studies implicating the Hh pathway in the pathogenesis of other hematologic malignancies and solid tumors[92]. Aberrant Hh signaling in cancer is postulated to occur through ligand-independent and ligand-dependent mechanisms (Figure 1B)[93]. Ligand-independent or mutation-driven signaling occurs when mutations in Hh pathway components—loss-of-function mutations in the negative regulators PTCH and SUFU (suppressor of fused), or gain-of-function mutations in the positive regulator SMO— lead to constitutive pathway activation within tumor cells. This type of signaling has been observed in basal cell carcinoma (PTCH and SMO mutations)[94, 95], medulloblastoma (PTCH and SUFU mutations)[96], and rhabdomyosarcoma (PTCH and SUFU loss of heterozygosity)[97].

Ligand-dependent mechanisms involve autocrine or paracrine Hh signaling[93]. During autocrine Hh signaling, tumor cells both secrete and respond to Hh—this type of Hh signaling has been identified in chronic myeloid leukemia (CML), small cell lung cancer, pancreatic cancer, breast cancer, and glioma[93]. Paracrine Hh signaling involves tumor-to-stroma or stroma-to-tumor (reverse paracrine) signaling. During tumor-to-stroma paracrine signaling, tumor cells produce and secrete Hh ligands which activate Hh signaling in surrounding stromal cells. Activated stromal cells release growth hormones which in turn stimulate tumor cell proliferation. Evidence for tumor-to-stroma paracrine signaling has been observed in pancreatic, colon, and prostate cancers[93]. Evidence for reverse paracrine signaling (stroma-to-tumor) in which Hh ligand produced in bone marrow stromal cells activates Hh signaling in surrounding tumor cells, has been reported for hematologic malignancies such as lymphoma, myeloid neoplasms, and multiple myeloma (MM)[91, 98]. In addition, the Hh pathway has been implicated in the maintenance and differentiation of cancer stem cells in CML, B-cell acute lymphocytic leukemia (B-ALL), and MM[50, 99, 100]. Moreover, up-regulation of Hh pathway components has been observed in the tumor stem cells of numerous hematologic malignancies, including BCR-ABL+ leukemic stem cells (LSCs)[65, 68], clonogenic B-ALL cells[87], CD34+ acute myeloid leukemia (AML)– and myelodysplastic syndromes (MDS)–derived cells[77], and MM CD138− tumor stem cells[91]. Pharmacologic inhibition of SMO has been shown to inhibit leukemogenesis through inhibition of LSC cell growth, self-renewal, and secondary transplantation capacity and induction of cell death in CML, AML, and ALL models (Table 2)[65, 68, 82‐88]. Hh signaling has also been implicated in the progression of CML in mouse bone marrow transplant models[65, 68]. Constitutively active Smo was shown to increase the frequency of CML stem cells and accelerate disease progression[68]. Conversely, genetic loss or pharmacologic inhibition of Smo significantly impaired CML progression and prolonged survival[65, 68]. These data suggest that the Hh signaling pathway plays a role in numerous hematologic malignancies, including MF, and its inhibition may block tumor stem cell growth and disease progression.

Several Hh pathway inhibitors that target SMO have demonstrated single-agent efficacy in patients with ligand-independent tumors[101‐105], including vismodegib, which was approved by the FDA in 2012 for the treatment of patients with locally advanced or metastatic basal cell carcinoma[101, 106]. Patients with Hh-activated medulloblastoma have also responded to treatment with vismodegib and the SMO inhibitor sonidegib[102, 104, 105]. Conversely, limited single-agent activity has been observed in ligand-dependent solid tumors—this lack of activity may be due in part to the contributions of other signaling pathways and stromal factors[107]. To date, saridegib (IPI-926), sonidegib, and PF-04449913 are the only SMO inhibitors that have been or are being tested in patients with MF (NCT01371617, NCT01787552, and NCT00953758, respectively) (Table 3). A phase 2 study of saridegib in patients with MF (NCT01371617) was halted following evaluation of an initial cohort of 12 patients—the level of clinical activity observed with saridegib did not meet the prespecified expansion criteria[108]. No further data have been reported. Data from a phase 1 trial of single-agent PF-04449913 presented at the American Society of Hematology in 2011 showed that PF-04449913 demonstrated activity in patients with refractory, resistant, or intolerant select hematologic malignancies, including MF (NCT00953758)[109]. The dose-limiting toxicity at 80 mg once daily was grade 3 hypoxia and pleural effusion. Of 6 patients with MF treated with PF-04449913, 5 achieved stable disease and 1 achieved clinical improvement with > 50% reduction in extramedullary disease. This patient remained on the study after 385 days and showed a spleen reduction from 10 to 3.5 cm over 8 weeks. Another patient achieved a marked reduction in bone marrow fibrosis.

These inhibitors, as well as the SMO inhibitors vismodegib (first in class) and BMS-833923, are being investigated in other hematologic malignancies, including ALL, AML/MDS, CML, and MM (Table 3)[111].

For maximization of the potential of Hh pathway inhibitor therapy in patients with MF and related myeloid malignancies such as MDS and AML, and demonstration of a benefit over current therapies, it will be important to develop a method to assess the association of Hh pathway inhibitor activity with efficacy. In other tumor types, GLI1 expression has been used to determine changes in Hh pathway activity and confirm targeted inhibition in patients treated with SMO inhibitors[99, 103, 104, 112, 113]. In patients with MF, AML, or CML, one study showed that gene expression analysis of bone marrow CD34+ LSCs before and after treatment with PF-04449913 showed up-regulation of growth arrest specific 1 and kinesin family member 27, 2 negative regulators of the Hh signaling pathway[113]. Although changes in the expression of downstream Hh pathway components can be used to detect Hh pathway repression, a more appropriate measure of Hh pathway inhibitor activity in patients with MF is evidence of disease modification through histopathologic (bone marrow fibrosis) and cytogenetic (JAK2 V617F allele burden) remission. In patients with MF with JAK2 V617F mutations, change in allele burden following treatment with a Hh pathway inhibitor would be an appropriate marker for stem cell inhibition. Similarly, for patients with MDS or AML disease-initiating mutations, reduction in allele burden would indicate a possible on-target effect. In patients without mutations, identification of an appropriate marker is yet to be accomplished. Sustained responses following treatment discontinuation may also reflect disease modification. Ultimately, in order to assess the efficacy of future targeted therapies, a combination of endpoints, including disease-specific histopathologic (ie, reduction of fibrosis) and molecular (ie, allele burden reduction) changes and clinical efficacy (ie, improvement in blood counts), should be considered. Future preclinical studies in JAK2 V617F–negative MF and correlative data from the ongoing trials of Hh pathway inhibitors in patients with MF may better define the optimal method for determination of efficacy and identification of predictive and pharmacodynamic biomarkers in patients treated with Hh pathway inhibitors.